# Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024

> **NCT06624384** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Mohsen Pourazizi** · enrollment: 150 (estimated)

## Conditions studied

- Ocular Surface Symptom
- Ocular Surface Disease
- Eye Pain
- Eye Inflammation

## Interventions

- **DRUG:** Group 1 drug
- **DRUG:** Group 2: Drug and placebo
- **DRUG:** Group 3: Drug and palcebo

## Key facts

- **NCT ID:** NCT06624384
- **Lead sponsor:** Mohsen Pourazizi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06624384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06624384, "Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06624384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*